drugset / Trial / NCT04552886
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
Phase 1
Completed
17 enrolled
The Cooper Health System
Baylor College of Medicine · collabPhiladelphia College of Osteopathic Medicine · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing standard-of-care treatments. Secondary outcomes will evaluate patient progression-free survival and overall survival.
Timeline
- Start
- 2021-10-11
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TH-1 Dendritic Cell Immunotherapy | Vaccine | 1.75 cells | — |
| Subject | TH-1 Dendritic Cell Immunotherapy | Vaccine | 3.5 cells | — |
| Subject | TH-1 Dendritic Cell Immunotherapy | Vaccine | 7 cells | — |
| Subject | TH-1 Dendritic Cell Immunotherapy | Vaccine | 14 cells | — |